{ "items": [ "\n\n
\n \n\n \n \n \n \n MSc IHTM News\n \n \n\n \n\n\n
\n \n\n \n2 June 2020
\n \n \n \nOur alumni Emilia Sitsofe Antonio and Sopuruchukwu Obiesie ( 2019-2020 cohort) as well as our alumni Zineb Bentounsi and Vitalis Fambombi Feteh (2018-2019 cohort), Gerald Jamberi Makuka and Roland Ngu (2017-2018 cohort) have contributed to this systematic review on independent trials aiming to answer similar questions.
\n \n\n \n \n\n \n\n \n \n \n \n OUCRU\n \n \n\n \n\n\n
\n \n\n \n1 June 2020
\n \n \n \nDespite a long border with China and a population of 97 million people, Vietnam has recorded only just over 300 cases of Covid-19 and not a single death. The country very quickly enacted measures such as travel restrictions, monitoring and eventually closing border with China, closing schools and increasing health checks at borders and other vulnerable places. A vast and labour intensive contact tracing operation got under way. Quarantine on such a vast scale is key as evidence mounts that as many as half of all infected people are asymptomatic.
\n \n\n \n \n\n \n\n \n \n \n \n General\n \n \n\n \n\n\n
\n \n\n \n29 May 2020
\n \n \n \nThe results of Mehra et al in The Lancet have had a considerable impact on public health practice and research, halted trials and caused considerable concern to participants and patients enrolled in randomised controlled trials (RCTs). This has led many researchers around the world to scrutinise in detail the publication and outline their concerns in this letter to Richard Horton, editor of The Lancet.
\n \n\n \n \n\n \n\n \n \n \n \n MSc IHTM News\n \n \n\n \n\n\n
\n \n\n \n25 May 2020
\n \n \n \nAlumnus Simon Mendelsohn (2015-2016) co-authored the publication from the study and development of a validated, simple blood-based test that has the potential to serve multiple functions in the fight against TB.
\n \n\n \n \n\n \n\n \n \n \n \n MORU\n \n \n\n \n\n\n
\n \n\n \n21 May 2020
\n \n \n \nA global study to test if either chloroquine or hydroxychloroquine can prevent COVID-19 in vital frontline healthcare workers will open to UK participants at hospital sites in Brighton and Oxford today.
\n \n\n \n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n20 May 2020
\n \n \n \nThe COVID-19 pandemic has seen some extraordinary medical feats and achievements, which are being rightly celebrated. Researchers at Oxford University have been at the forefront of global efforts, including the first human trials of a COVID-19 vaccine, and the world\u2019s biggest trial of potential COVID-19 treatments, RECOVERY.
\n \n\n \n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n12 May 2020
\n \n \n \nThe COVID-19 International Modelling Consortium (CoMo Consortium) was created by researchers at the University of Oxford and Cornell University, is partnering with infectious disease modellers and public health experts from over 40 countries in Africa, Asia and America. The CoMo Consortium uses a participatory approach to provide decision-making support to policymakers, using evidence from epidemiological and economic models adapted to each country\u2019s context.
\n \n\n \n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n5 May 2020
\n \n \n \nThe Global Health Network and the Family Larsson Rosenquist Foundation (FLRF) launch LactaHub: an open access knowledge platform featuring scientific and evidence-based information on breastfeeding and breastmilk for health professionals
\n \n\n \n \n\n \n\n \n \n \n \n MORU\n \n \n\n \n\n\n
\n \n\n \n1 May 2020
\n \n \n \nThe SEBCOV study aims to produce evidence to inform public health measures such as communications, quarantine, self-isolation, social distancing and travel restrictions for the COVID-19 pandemic. This study is run in four countries: UK, Thailand, Italy and Malaysia.
\n \n\n \n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n30 April 2020
\n \n \n \nThe results of a placebo-controlled randomised trial of remdesivir in COVID-19 patients have been published in the Lancet. Supported by the ISARIC Support Centre, scientists in China launched a trial of remdesivir in patients hospitalised with COVID-19. The results found no clinical benefit from use of the drug; however, while not statistically significant, the time to clinical improvement and duration of invasive mechanical ventilation were shorter in people treated with remdesivir.
\n \n\n \n \n\n \n\n \n \n \n \n MORU\n \n \n\n \n\n\n
\n \n\n \n29 April 2020
\n \n \n \nThe Epidemiology Department of MORU and National Malaria Control Programme, Cambodia (CNM) have begun to implement a study to assess the efficacy of prophylaxis with artemether-lumefantrine (PAL) against forest malaria in Siem Pang District, north-eastern Cambodia bordering Laos.
\n \n\n \n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n27 April 2020
\n \n \n \nThe International Severe Acute Respiratory and Emerging Infections Consortium (ISARIC) is producing a weekly report using clinical data from its COVID-19 database. To date, this includes data from 19,809 individuals from 244 sites across 25 countries.
\n \n\n \n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n25 April 2020
\n \n \n \nBlog by Rima Shretta, Honorary Visiting Research Fellow. As the COVID-19 pandemic continues its path to LMICs, its impact is likely to be even more devastating, potentially reversing recent gains made in the management of other communicable diseases. Of particular concern is the impact of the COVID-19 pandemic on malaria. COVID-19 has been slow to arrive and spread across Africa; nevertheless, there are many reasons to be concerned about malaria within the current context of the COVID-19 pandemic.
\n \n\n \n \n\n \n\n \n \n \n \n MORU\n \n \n\n \n\n\n
\n \n\n \n24 April 2020
\n \n \n \nThe impact of COVID-19 is quite evident at present \u2013 entire countries and cities are under lockdown, offices and industries shut and academia at a standstill. However, many people in Bangladesh remain unaware or indifferent to the warnings and safety protocols that ought to be followed to stop COVID-19\u2019s spread. Since enforcing social distancing in a densely populated country like Bangladesh is very challenging, making people aware and maintenance of hygiene are the main means to stop the spread of COVID-19.
\n \n\n \n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n24 April 2020
\n \n \n \nA site team in Malawi used the WWARN Malaria Clinical Trials Toolkit for their antimalarial-antiretroviral drug-drug interaction trial with pregnant women. Clifford Banda and his staff used the CDISC-compliant WWARN REDCap data base template as the basis for their data collection and capture, and used or adapted the many WWARN standard operating procedures and their forms for various administrative, clinical, investigational product, quality, data management and safety aspects of their planned work.
\n \n\n \n \n\n \n\n \n \n \n \n COMRU\n \n \n \n \n LOMWRU\n \n \n \n \n MORU\n \n \n\n \n\n\n
\n \n\n \n23 April 2020
\n \n \n \nLess than a month after it was announced, the MORU-led COPCOV study has made quick progress and expects to begin enrolling participants by the end of April.
\n \n\n \n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n17 April 2020
\n \n \n \nThe UK government is funding 21 new novel coronavirus research studies, including a project led by Professor Trudie Lang. Research must be undertaken everywhere across the globe during this pandemic. Access and ability to undertake research should be equitable, and this research project, working through The Global Health Network, aims to support healthcare teams in low-resource settings. This is a University of Oxford led programme aiming to enable more and better research in diseases, communities and settings where evidence is lacking.
\n \n\n \n \n\n \n\n \n \n \n \n MORU\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n10 April 2020
\n \n \n \nGlobal health experts have united in a call for governments and international organisations around the world to plan strategically for the coordinated production, equitable distribution and surveillance of COVID-19 medical products to ensure access to quality-assured medications for everyone.
\n \n\n \n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n7 April 2020
\n \n \n \nBlog by Rima Shretta, Honorary Visiting Research Fellow. Rima outlines the direct and indirect costs of the COVID-19 pandemic which may impact the global economy.
\n \n\n \n \n\n \n\n \n \n \n \n MORU\n \n \n \n \n Video\n \n \n\n \n\n\n
\n \n\n \n6 April 2020
\n \n \n \nThere are currently no proven vaccines or drugs to prevent COVID-19. In this BBC World News interview, MORU\u2019s Prof Sir Nick White explains why the only way to find out if chloroquine and hydroxychloriquine work against COVID-19 is via randomised, clinical trials and how the hype over chloroquine negatively affects people with lupus and rheumatoid arthritis.
\n \n\n \n \n